©IDOSR PUBLICATIONS International Digital Organization for Scientific Research

IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 47-51, 2026 ISSN: 2579-0781

https://doi.org/10.59298/IDOSR/JES/06/1224751 IDOSRJES12206

Gut Microbiome-Derived Metabolites as Biomarkers for Insulin Resistance in Gestational Diabetes

Kabazzi Douglas T.

Department of Pharmaceutics Kampala International University Uganda
Email: t.kabazzi@studwc.kiu.ac.ug

ABSTRACT

Gestational diabetes mellitus was a major pregnancy complication driven largely by insulin resistance, and its prevalence remained substantial worldwide, affecting about 4 to 16.5% of pregnancies, with a pooled global standardized prevalence of 14.0% in one meta-analytic estimate. This narrative review examined how gut microbiome-derived metabolites, especially short chain fatty acids, bile acids, and trimethylamine N oxide related compounds, may serve as biomarkers for insulin resistance in gestational diabetes, with emphasis on their biological plausibility and clinical utility. The article was written by synthesizing recent peer reviewed literature on gut microbiota, metabolic profiling, and gestational diabetes to identify recurring mechanistic and diagnostic themes. The reviewed evidence suggested that altered metabolite patterns in gestational diabetes correlated with glucose and lipid disturbances and may support early detection, risk stratification, and future therapeutic targeting. Serum and fecal metabolomic signatures have identified discriminatory metabolites with reasonable diagnostic performance, although validation in larger and ethnically diverse cohorts remains necessary. Overall, microbiome-derived metabolites are promising biomarker candidates, but standardization, longitudinal sampling, and integration with clinical data are required before routine use.

Keywords: Gestational diabetes, Insulin resistance, Gut microbiome, Metabolites, Biomarkers.

INTRODUCTION

Gestational diabetes mellitus is defined by glucose intolerance first recognized during pregnancy and is tightly linked to progressive insulin resistance, pancreatic beta cell stress, and adverse maternal fetal outcomes [1–3]. Because pregnancy is already a metabolically dynamic state, the emergence of insulin resistance in gestation can expose a vulnerable metabolic phenotype that influences both short term and long-term health in mother and child. The clinical burden is considerable: recent estimates suggest that gestational diabetes affects roughly 4 to 16.5% of pregnant women worldwide, while standardized global prevalence has been estimated at 14.0%, with marked regional variation. Such figures underscore a persistent public health problem, especially in Africa, South East Asia, and the Middle East and North Africa, where prevalence may be particularly high [4].

The pathobiology of gestational diabetes is not limited to maternal adiposity or beta cell dysfunction. Growing evidence indicates that the gut microbiome participates in host energy balance, inflammatory tone, bile acid signaling, and glucose homeostasis, all of which may influence insulin sensitivity during pregnancy. In this context, microbiome-derived metabolites have become attractive biomarker candidates because they offer a functional readout of host microbe interaction rather than a static taxonomic profile alone [5]. This perspective is especially important for clinicians and researchers who require markers that reflect disease activity, not merely association [6]. This review therefore addresses five interrelated areas. First, it outlines the mechanistic basis for gut microbiome metabolite production in gestational diabetes. Second, it examines major metabolite classes linked to insulin resistance, including short chain fatty acids, bile acids, and trimethylamine N oxide related pathways. Third, it evaluates how these metabolites may improve biomarker discovery and diagnostic discrimination in gestational diabetes. Fourth, it considers methodological and translational limitations that currently restrict

clinical application. Fifth, it offers a practical recommendation for future biomarker development. The purpose of this article is to provide a concise but scholarly synthesis of current evidence on gut microbiome-derived metabolites as biomarkers for insulin resistance in gestational diabetes and to clarify their future research and clinical relevance.

Microbiome and Pregnancy

Pregnancy reshapes host metabolism, immunity, and intestinal ecology, creating a biological setting in which gut microbial shifts may have stronger metabolic consequences than in the non-pregnant state [7]. Studies comparing women with gestational diabetes and healthy pregnant controls consistently show differences in microbial composition and functional metabolism, suggesting that dysbiosis may accompany or contribute to insulin resistance. Although microbial diversity findings are not uniform across studies, the broader signal is that pregnancy associated dysbiosis is biologically plausible and clinically relevant [8].

The gut microbiota affects insulin sensitivity through several routes. It regulates intestinal barrier integrity, modulates low grade inflammation, influences endotoxin translocation, and produces metabolites that act on hepatic, adipose, and pancreatic targets [9]. In gestational diabetes, these pathways may amplify inflammatory signaling and impair glucose disposal, thereby worsening insulin resistance. This is particularly important because the phenotype of gestational diabetes is not simply hyperglycemia, but a coordinated metabolic disturbance in which inflammatory and hormonal signaling intersect [10]. A key strength of microbiome research is its ability to connect ecological change with metabolic output [11]. Rather than focusing only on taxa, metabolomic profiling captures the downstream products of microbial activity and host metabolism. This makes metabolite-based biomarkers especially relevant in gestational diabetes, where dynamic metabolic adaptation may be more informative than single time point microbiome snapshots. The emerging view is that the microbiome should be interpreted as a functional endocrine organ whose metabolites may mirror insulin resistant physiology [12].

Short Chain Fatty Acids

Short chain fatty acids, especially acetate, propionate, and butyrate, are among the best studied microbial metabolites in metabolic disease [13, 14]. They are generated mainly through bacterial fermentation of nondigestible carbohydrates and influence appetite regulation, gut barrier function, inflammation, and insulin signaling. In gestational diabetes, altered short chain fatty acid profiles have been repeatedly reported, suggesting that reduced or distorted fermentation products may reflect disrupted microbial metabolism [8].

The clinical significance of short chain fatty acids lies in their dual role as functional mediators and measurable analytes. Some studies report that specific branched chain and related fatty acids, such as isobutyric acid, isovaleric acid, valeric acid, and caproic acid, are elevated in women with gestational diabetes and correlate with glucose and lipid abnormalities. These findings imply that not all short chain fatty acid changes are uniformly protective; rather, the pattern, proportion, and metabolic context matter. In a disease state characterized by insulin resistance, altered fermentation may reflect dietary shifts, microbial imbalance, or host compensatory responses [12].

From a biomarker standpoint, short chain fatty acids are attractive because they are measurable in serum and feces and may be combined into multianalyte panels. However, their interpretation requires care. Levels can vary by diet, sampling method, gestational age, and antibiotic exposure, which limits their use as standalone markers. Even so, their biological relevance to intestinal signaling and peripheral insulin action places them at the center of biomarker research in gestational diabetes [15].

Bile Acid Signaling

Bile acids are no longer viewed solely as digestive detergents; they are signaling molecules that influence glucose metabolism through receptors such as farnesoid X receptor and TGR5 [16, 17]. The gut microbiota modifies primary bile acids into secondary and conjugated forms, thereby shaping systemic metabolic signaling. In gestational diabetes, this pathway appears especially important because bile acid dysregulation can influence insulin sensitivity, hepatic gluconeogenesis, and inflammatory responses [10]. Recent metabolomic studies have identified altered bile acid patterns in gestational diabetes, including increased GUDCA, THDCA plus TUDCA, and LCA 3S in comparison with healthy pregnancy controls [18, 19]. Such changes suggest that gestational diabetes is associated with a remodeled bile acid pool, potentially driven by microbiome shifts. Since bile acids can act as endocrine mediators, their altered abundance may provide both mechanistic insight and biomarker value [12]. Bile acid-based biomarkers are promising because they may capture the interaction between microbial enzymatic activity and host metabolic adaptation. They may also be more pathophysiologically informative than simple microbial abundance measures, especially when paired with glucose and lipid indices. Nevertheless, clinical translation remains limited by analytical complexity, intra individual variability, and the need for gestational age specific reference ranges. The most realistic near term application is not isolated bile acid testing, but incorporation into composite biomarker models [8].

TMAO and Related Markers

Trimethylamine N oxide and its related metabolites have attracted attention because they link microbiota dependent choline and carnitine metabolism to cardiometabolic disease [20]. In gestational diabetes, however, the

current evidence is less consistent than for short chain fatty acids and bile acids. One targeted metabolomics study found that TMAO and its derivatives did not differ significantly between women with gestational diabetes and healthy controls, despite other metabolite changes being clear. This suggests that TMAO may not be a dominant biomarker in all gestational diabetes populations [12]. Even so, TMAO related biology should not be dismissed. It remains a relevant candidate because it represents a distinct microbial pathway and may interact with inflammation, lipid metabolism, and vascular risk. Its usefulness may depend on population characteristics, dietary patterns, renal function, and the timing of measurement. In pregnant populations, these factors can vary widely and may obscure true biological signal [8]. For now, TMAO appears better suited as a component of broader metabolite panels than as a solitary marker. Its main value may lie in refining mechanistic models of microbiome host interaction rather than serving as a primary diagnostic tool. Future studies should determine whether TMAO adds predictive value when combined with bile acids, short chain fatty acids, and traditional clinical measures [15].

Biomarker Translation

The strongest argument for microbiome derived metabolites is that they may detect insulin resistant biology before overt disease becomes clinically obvious [21]. In one serum-based study, multiple metabolites showed significant differences between gestational diabetes and healthy pregnancy, and receiver operating characteristic analysis indicated that these metabolites may function as potential biomarkers. A separate multi omics study also found discriminatory fecal and urinary metabolites and developed a combinatorial marker panel with high accuracy for distinguishing gestational diabetes from controls. Such findings are encouraging because they suggest that metabolite panels may outperform single analytes [22]. Translation to practice, however, requires more than statistical discrimination. Biomarkers must be reproducible across cohorts, robust to diet and treatment effects, and feasible for routine laboratory use. Longitudinal validation is especially important because gestational diabetes evolves across pregnancy, and a useful biomarker should ideally predict risk before diagnosis, not merely confirm it afterward. This means future research should prioritize early gestation sampling, standardized analytic methods, and integration with body mass index, family history, and glucose testing [15]. A practical model is emerging in which microbiome metabolites complement existing screening rather than replace it. For example, a panel of bile acids plus short chain fatty acids may better capture metabolic stress than fasting glucose alone, while also providing mechanistic insight. Such a strategy is more realistic for clinical adoption and more aligned with the multidimensional biology of gestational diabetes [12].

CONCLUSION

Gut microbiome-derived metabolites represent a compelling class of candidate biomarkers for insulin resistance in gestational diabetes because they reflect the functional interface between microbial ecology, host metabolism, and inflammatory signaling. Evidence to date supports meaningful alterations in short chain fatty acids and bile acid profiles, with some studies showing correlation with glucose and lipid disturbances and diagnostic discrimination between gestational diabetes and healthy pregnancy. The available literature also suggests that microbial metabolic signatures may be more informative than taxonomy alone, because they capture biochemical consequences of dysbiosis rather than its descriptive composition. Nevertheless, present findings are still limited by small sample sizes, heterogeneity in analytical platforms, and the lack of universally accepted metabolite thresholds. For clinical science, the most important implication is that these metabolites may become useful as early screening adjuncts, risk stratification tools, and mechanistic biomarkers if validated in longitudinal, multiethnic cohorts. Future studies should develop standardized, multi metabolite panels and test them prospectively against current gestational diabetes screening methods.

REFERENCES

1. Modzelewski, R., Stefanowicz-Rutkowska, M.M., Matuszewski, W., Bandurska-Stankiewicz, E.M.: Gestational Diabetes Mellitus—Recent Literature Review. Journal of Clinical Medicine. 11, 5736 (2022). https://doi.org/10.3390/jcm11195736
2. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I. Beyond Pregnancy: Understanding the Long Term Implications of Gestational Diabetes Mellitus. *INOSR Scientific Research*. 2024; 11(1):63-71. https://doi.org/10.59298/INOSRSR/2024/1.1.16371
3. Ugwu, O.P.-C., Erisa, K., Obeagu., E.I., Alum, E.U., Michael B, O., Subbarayan, S., Sankarapandiyan, V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. INOSR ES. 12, 214–224 (2023). https://doi.org/10.59298/INOSRES/2023/2.17.1000
4. Sartayeva, A., Danyarova, L., Begalina, D., Nurgalieva, Z., Baikadamova, L., Adilova, G.: GESTATIONAL DIABETES: PREVALENCE AND RISKS FOR THE MOTHER AND CHILD (REVIEW). Georgian Med News. 47–52 (2022)

5. Egwu, C. K., Edeh, F. O., & Alum, B. N. (2026). Microbiota as a therapeutic target for metabolic inflammation: Promise or illusion? Human Nutrition & Metabolism, 45, 200370. https://doi.org/10.1016/j.hnm.2026.200370
6. Ionescu, R.F., Enache, R.M., Cretoiu, S.M., Gaspar, B.S.: Gut Microbiome Changes in Gestational Diabetes. Int J Mol Sci. 23, 12839 (2022). https://doi.org/10.3390/ijms232112839
7. Amato, K.R., Pradhan, P., Mallott, E.K., Shirola, W., Lu, A.: Host–gut microbiota interactions during pregnancy. Evol Med Public Health. 12, 7–23 (2024). https://doi.org/10.1093/emph/eoae001
8. Wang, X., Liu, H., Li, Y., Huang, S., Zhang, L., Cao, C., Baker, P.N., Tong, C., Zheng, P., Qi, H.: Altered gut bacterial and metabolic signatures and their interaction in gestational diabetes mellitus. Gut Microbes. 12, 1–13 (2020). https://doi.org/10.1080/19490976.2020.1840765
9. Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L.R., Scaldaferri, F.: Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 19, 275–293 (2024). https://doi.org/10.1007/s11739-023-03374-w
10. Ren, Y., Zeng, Y., Wu, Y., Yu, J., Zhang, Q., Xiao, X.: The Role of Gut Microbiota in Gestational Diabetes Mellitus Affecting Intergenerational Glucose Metabolism: Possible Mechanisms and Interventions. Nutrients. 15, 4551 (2023). https://doi.org/10.3390/nu15214551
11. Lindsay, E.C., Metcalfe, N.B., Llewellyn, M.S.: The potential role of the gut microbiota in shaping host energetics and metabolic rate. Journal of Animal Ecology. 89, 2415–2426 (2020). https://doi.org/10.1111/1365-2656.13327
12. Gao, Y., Chen, H., Li, J., Ren, S., Yang, Z., Zhou, Y., Xuan, R.: Alterations of gut microbiota-derived metabolites in gestational diabetes mellitus and clinical significance. Journal of Clinical Laboratory Analysis. 36, e24333 (2022). https://doi.org/10.1002/jcla.24333
13. Aniokete, U. C., Emeruwa, A. P., Obasi, D. C., Okoroh, P. N., … & Aja, P. M. (2025). Gut microbiota at the crossroads of food additives, pollutants, and chronic disease risk. Toxicology and Environmental Health Sciences. https://doi.org/10.1007/s13530-025-00295-3
14. Tufail, T., Govindarajan, R.K., Nwuruku, O.A., Aja, P.M. Gut Microbiota Resilience and Environmental Stressors: A Hidden Key to Lifespan Optimization? Probiotics Antimicrob Proteins. 2026 Mar 17. doi: 10.1007/s12602-026-10976-1. Epub ahead of print. PMID: 41843355.
15. Ma, S., Wang, Y., Ji, X., Dong, S., Wang, S., Zhang, S., Deng, F., Chen, J., Lin, B., Khan, B.A., Liu, W., Hou, K.: Relationship between gut microbiota and the pathogenesis of gestational diabetes mellitus: a systematic review. Front Cell Infect Microbiol. 14, 1364545 (2024). https://doi.org/10.3389/fcimb.2024.1364545
16. Emeruwa, A. P., Obasi, D. C., Okoroh, P. N., Aniokete, U. C., Akwari, A. Ak., Uzor, S., Eji, M. O., & Amadi, E. B. (2026). Gut microbiome-derived metabolites as predictors of bariatric surgery outcomes. Clinica Chimica Acta, 121153. https://doi.org/10.1016/j.cca.2026.121153
17. Lin, X., Xia, L., Zhou, Y., Xie, J., Tuo, Q., Lin, L., Liao, D.: Crosstalk Between Bile Acids and Intestinal Epithelium: Multidimensional Roles of Farnesoid X Receptor and Takeda G Protein Receptor 5. International Journal of Molecular Sciences. 26, 4240 (2025). https://doi.org/10.3390/ijms26094240
18. Zhao, F., Zhang, L., Qu, M., Ye, L., Zhang, J., Yu, Y., Huang, Q., Zhang, C., Wang, J.: Obeticholic acid alleviates intrauterine growth restriction induced by di-ethyl-hexyl phthalate in pregnant female mice by improving bile acid disorder. Environ Sci Pollut Res. 30, 110956–110969 (2023). https://doi.org/10.1007/s11356-023-30149-9
19. Wu, Y., Wang, Z., Zhao, Z., Song, X., Miao, M., Zhang, X.: Bile acid metabolites in early pregnancy and risk of gestational diabetes mellitus: Results from a prospective cohort study. Diabetes, Obesity and Metabolism. 25, 2255–2267 (2023). https://doi.org/10.1111/dom.15104
20. Zhen, J., Zhou, Z., He, M., Han, H.-X., Lv, E.-H., Wen, P.-B., Liu, X., Wang, Y.-T., Cai, X.-C., Tian, J.-Q., Zhang, M.-Y., Xiao, L., Kang, X.-X.: The gut microbial metabolite trimethylamine N-oxide and cardiovascular diseases. Front. Endocrinol. 14, (2023). https://doi.org/10.3389/fendo.2023.1085041
21. Régnier, M., Van Hul, M., Knauf, C., Cani, P.D.: Gut microbiome, endocrine control of gut barrier function and metabolic diseases. J Endocrinol. 248, R67–R82 (2021). https://doi.org/10.1530/JOE-20-0473
22. Beldie, L.-A., Dica, C.-C., Moța, M., Pirvu, B.-F., Burticală, M.-A., Mitrea, A., Clenciu, D., Efrem, I.C., Vladu, B.E., Timofticiuc, D.C.P., Roşu, M.M., Gheonea, T.C., Amzolini, A.M., Moța, E., Vladu, I.M.: The Interactions Between Diet and Gut Microbiota in Preventing Gestational Diabetes Mellitus: A Narrative Review. Nutrients. 16, 4131 (2024). https://doi.org/10.3390/nu16234131

CITE AS: Kabazzi Douglas T. (2026). Gut Microbiome-Derived Metabolites as Biomarkers for Insulin Resistance in Gestational Diabetes. IDOSR JOURNAL OF EXPERIMENTAL SCIENCES 12(2): 47-51. https://doi.org/10.59298/IDOSR/JES/06/1224751